Clinical Trial Update: A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating regorafenib plus lorigerlimab as neoadjuvant therapy for colorectal cancer was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Lorigerlimab (lorigerlimab)
• Regorafenib (regorafenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Colorectal Cancer | Phase 1, Phase 2 | Status: WITHDRAWN